Disease burden of patients with pemphigus from a societal perspective

References

• Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev. 2014 Apr-May;13(4–5):477–481.
   PubMed Web of Science ®Google Scholar
• Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality. Acta Derm Venereol. 2017 Oct 2;97(9):1095–1099.
   PubMed Web of Science ®Google Scholar
• Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev. 2010 Mar;9(5):A379–82.
   PubMed Web of Science ®Google Scholar
• Sebaratnam DF, McMillan JR, Werth VP, et al. Quality of life in patients with bullous dermatoses. Clin Dermatol. 2012 Jan-Feb;30(1):103–107.
   PubMed Web of Science ®Google Scholar
• Rencz F, Brodszky V, Stalmeier PF, et al. Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. Br J Dermatol. 2016 Sep;175(3):593–599.
   PubMed Web of Science ®Google Scholar
• Rencz F, Gulacsi L, Tamasi B, et al. Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. Br J Dermatol. 2015 Oct;173(4):1076–1080.
   PubMed Web of Science ®Google Scholar
• Tamasi B, Brodszky V, Pentek M, et al. Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2019 Apr;180(4):802–809.
   PubMed Web of Science ®Google Scholar
• Hajdu K, Brodszky V, Stalmeier PFM, et al. Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. J Eur Acad Dermatol Venereol. 2019;33:2106–2113. [Accepted for publication].
   PubMed Web of Science ®Google Scholar
• Mitev A, Rencz F, Tamasi B, et al. Subjective well-being in patients with pemphigus: a path analysis. Eur J Health Econ. 2019 Jun;20(Suppl 1):101–107.
   PubMedGoogle Scholar
• Wang EQ, Radjenovic M, Castrillon MA, et al. The effect of autoimmune blistering diseases on work productivity. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1959–1966.
   PubMed Web of Science ®Google Scholar
• Heelan K, Hitzig SL, Knowles S, et al. Loss of work productivity and quality of life in patients with autoimmune bullous dermatoses. J Cutan Med Surg. 2015 Nov-Dec;19(6):546–554.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018 Feb 10.pii: S0190-9622(18)30207-X. doi: 10.1016/j.jaad.2018.02.021. [Epub ahead of print] PubMed PMID: 29438767.
   PubMed Web of Science ®Google Scholar
• Hebert V, Joly P. Rituximab in pemphigus. Immunotherapy. 2018 Jan;10(1):27–37.
   PubMed Web of Science ®Google Scholar
• Harman KE, Brown D, Exton LS, et al. British association of dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017 Nov;177(5):1170–1201.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Sprecher E. Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2017 Nov;177(5):1143–1144.
   PubMed Web of Science ®Google Scholar
• Adamson AS. The economics burden of atopic dermatitis. Adv Exp Med Biol. 2017;1027:79–92.
   PubMed Web of Science ®Google Scholar
• Lichterfeld-Kottner A, Hahnel E, Blume-Peytavi U, et al. Systematic mapping review about costs and economic evaluations of skin conditions and diseases in the aged. J Tissue Viability. 2017 Feb;26(1):6–19.
   PubMed Web of Science ®Google Scholar
• Politiek K, Oosterhaven JA, Vermeulen KM, et al. Systematic review of cost-of-illness studies in hand eczema. Contact Dermatitis. 2016 Aug;75(2):67–76.
   PubMed Web of Science ®Google Scholar
• Jungen D, Augustin M, Langenbruch A, et al. Cost-of-illness of psoriasis - results of a German cross-sectional study. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):174–180.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Burudpakdee C, Gala S, et al. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):685–705.
   PubMed Web of Science ®Google Scholar
• Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014 Dec;20(4):327–337.
   PubMedGoogle Scholar
• Greenberg D, Mohamed Ibrahim MIB, Boncz I. What are the challenges in conducting cost-of-illness studies? Value Health Reg Issues. 2014 Sep;4:115–116.
   PubMedGoogle Scholar
• Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatol. 2016 Jun 1; 152(6):645–654.
   PubMed Web of Science ®Google Scholar
• Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the nationwide inpatient sample. J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1768–1776.
   PubMed Web of Science ®Google Scholar
• Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol. 2006 Apr;6(4):600–606.
   PubMed Web of Science ®Google Scholar
• Heelan K, Hassan S, Bannon G, et al. Cost and resource use of pemphigus and pemphigoid disorders pre- and post-rituximab. J Cutan Med Surg. 2015 May-Jun;19(3):274–282.
   PubMed Web of Science ®Google Scholar
• Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;Oct;10(4):357–359.
   PubMed Web of Science ®Google Scholar
• Knies S, Severens JL, Ament AJ, et al. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines. Value Health. 2010 Aug;13(5):519–527.
   PubMed Web of Science ®Google Scholar
• Kigozi J, Jowett S, Lewis M, et al. The estimation and inclusion of presenteeism costs in applied economic evaluation: a systematic review. Value Health. 2017 Mar;20(3):496–506.
   PubMed Web of Science ®Google Scholar
• Gulacsi L, Rotar AM, Niewada M, et al. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ. 2014 May;15(Suppl 1):S13–25.
   PubMedGoogle Scholar
• EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018 Jan;27(1):7–22.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005 Oct;125(4):659–664.
   PubMed Web of Science ®Google Scholar
• Pfutze M, Niedermeier A, Hertl M, et al. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007 Jan-Feb;17(1):4–11.
   PubMed Web of Science ®Google Scholar
• Daniel BS, Hertl M, Werth VP, et al. Severity score indexes for blistering diseases. Clin Dermatol. 2012 Jan-Feb;30(1):108–113.
   PubMed Web of Science ®Google Scholar
• Hanna S, Kim M, Murrell DF. Validation studies of outcome measures in pemphigus. Int J Womens Dermatol. 2016 Dec;2(4):128–139.
   PubMedGoogle Scholar
• Boulard C, Duvert Lehembre S, Picard-Dahan C, et al. Calculation of cut-off values based on the Autoimmune bullous skin disorder intensity score (ABSIS) and Pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016 Jul;175(1):142–149.
   PubMed Web of Science ®Google Scholar
• Hungarian Cenral Bank, official exchange rates; 2017 [Cited 2018 Dec 3]. Available from: https://www.mnb.hu/arfolyam-lekerdezes
   Google Scholar
• Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev. 2006 Apr;63(2):217–235.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• National Health Insurance Fund of Hungary. Diagnosis-related groups (DRG) classification scheme 5.0; 2017 [Cited 2018 Jan 10]. Available from: http://www.neak.gov.hu/data/cms1018548/Hbcs50_torzs_20171213.xls
   Google Scholar
• National Health Insurance Fund of Hungary. National price list of pharmaceuticals; 2017 [Cited 2018 Jan 10]. Available from: http://www.neak.gov.hu//data/cms1018933/PUPHA_GYOGYSZER_LAKOSSAGI_20180201_v2.xls
   Google Scholar
• Oliva-Moreno J, Trapero-Bertran M, Pena-Longobardo LM, et al. The valuation of informal care in cost-of-illness studies: a systematic review. Pharmacoeconomics. 2017 Mar;35(3):331–345.
   PubMed Web of Science ®Google Scholar
• Hungarian Central Statistical Office. First releases: earnings; 2017 [Cited 2018 Jan 10]. Available from: http://www.ksh.hu/gyorstajekoztatok/#/hu/document/ker1709
   Google Scholar
• Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000 Dec 15;19(23):3219–3236.
   PubMed Web of Science ®Google Scholar
• Malehi AS, Pourmotahari F, Angali KA. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Econ Rev. 2015;5:11.
   PubMed Web of Science ®Google Scholar
• Balogh O, Brodszky V, Gulacsi L, et al. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ. 2014 May;15(Suppl 1):S101–9.
   PubMedGoogle Scholar
• Minier T, Pentek M, Brodszky V, et al. Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford). 2010 Oct;49(10):1920–1928.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Balint P, Geher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int. 2009 Dec;30(2):199–205.
   PubMed Web of Science ®Google Scholar
• Polistena B, Calzavara-Pinton P, Altomare G, et al. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2411–2416.
   PubMed Web of Science ®Google Scholar
• Heredi E, Rencz F, Balogh O, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014 May;15(Suppl 1):S111–9.
   PubMedGoogle Scholar
• Rencz F, Gulacsi L, Pentek M, et al. Proposal of a new scoring formula for the dermatology life quality index in psoriasis. Br J Dermatol. 2018 Nov;179(5):1102–1108.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Finlay AY, Salek SS, et al. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429–1439.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German registry of autoimmune diseases. J Dtsch Dermatol Ges. 2012 Oct;10(10):727–732.
   PubMed Web of Science ®Google Scholar
• Shah AA, Seiffert-Sinha K, Sirois D, et al. Development of a disease registry for autoimmune bullous diseases: initial analysis of the pemphigus vulgaris subset. Acta Derm Venereol. 2015 Jan;95(1):86–90.
   PubMed Web of Science ®Google Scholar